The study was conducted at the Preston Robert Tisch Brain Tumor Center (BTC) at Duke University Medical Center (DUMC) in Durham, North Carolina. Potential participants consisted of all brain tumor patients seen at the BTC between August 2003 and February 2005. Additional inclusion criteria were 1) histologically confirmed primary brain cancer, 2) the patient being of legal age, 3) approval of the patient's primary treating oncologist, and 4) the patient's ability to understand and provide written informed consent in English. Institutional review board approval was obtained before commencement of the study. Using a cross-sectional design, potential participants were identified and screened through the BTC cancer database at DUMC and oncologist approval to contact patients was pursued. After approval, each potential participant was sent a questionnaire package that contained a detailed cover letter; 2 copies of a consent form; a questionnaire; and a stamped, self-addressed return envelope. Survey methods known to increase response rates were used, including multiple reminders (e.g., telephone calls), stamped return envelopes, personalized cover letters, colored paper, assurances of confidentiality, a small incentive of 3 commemorative postage stamps, and BTC sponsorship.